What is antibody de-immunization?

Antibody de-immunization involves modifying therapeutic antibodies to reduce their immunogenicity, or the likelihood of triggering an immune response in patients. This process typically utilizes various engineering techniques to alter parts of the antibody that are recognized by the immune system, thus enhancing its compatibility and safety for clinical use.

How is antibody engineering used in de-immunization?

Antibody engineering for de-immunization involves techniques such as altering the amino acid sequence of the antibody to remove T-cell epitopes while maintaining its antigen-binding ability. Techniques like CDR grafting, humanization, and phage display are commonly employed to achieve these modifications effectively.

What are the benefits of antibody de-immunization?

The primary benefit of antibody de-immunization is the reduced risk of immune responses against the therapeutic antibody, which can lead to adverse effects and decreased efficacy. De-immunized antibodies can provide more consistent therapeutic results and improved patient tolerance, especially in chronic conditions requiring long-term treatment.

Can all antibodies be de-immunized?

While most antibodies can be engineered for reduced immunogenicity, the success of de-immunization depends on the specific characteristics of the antibody and its target. Factors such as the antibody's origin, structure, and the epitopes involved can influence the feasibility and outcome of the de-immunization process.

How is the effectiveness of de-immunized antibodies measured?

The effectiveness of de-immunized antibodies is typically assessed through preclinical and clinical trials that evaluate their safety, immunogenicity, and therapeutic efficacy. Analytical techniques such as ELISA, mass spectrometry, and immune assays are used to characterize the modified antibodies and their interaction with the immune system.

RDIT^® Antibody Engineering Service

Introduction De-immunization by Antibody Engineering Features FAQ Resources

Antibody engineering refers to the engineering of transforming and reassembling antibody genes by recombinant DNA and protein engineering techniques, and transfecting appropriate recipient cells to express antibody molecules. It can also engineer antibody molecules by cell fusion, chemical modification, and other methods used to reduce the immunogenicity of drugs. With more than ten years of continuous knowledge expansion and experience accumulation, Creative Biolabs provides you with the latest antibody engineering tools and technical services with confidence to reduce the immune response of drugs in the body, thereby improving the efficacy of the drug.

Introduction of Antibody Engineering

The engineering form of antibody drugs is designed to minimize their immunogenicity. The methods include humanization and selection of fully human antibodies. The strategy of antibody engineering and process development was used to optimize the amino acid sequence of the molecule and its behavior under process conditions. It is worth noting that even fully human antibody therapy can be immunogenic due to the inherent sequence variability of antibody in the variable domain, so it can induce a significant immune response.

Fig.1 Schematic overview of antibody humanization from murine antibodies (red domains) to fully human antibodies (blue domains). (Santos, 2018)

De-immunization by Antibody Engineering

At present, some studies have shown that CD4⁺ T cell epitopes only exist in the inclusion region of complementarity-determining residue (CDR) sequence, but not in framework regions (FRs). It can be concluded that in humanized antibodies and fully human antibodies:
I) CDRs are the only segments that may contain CD4⁺ T cell epitopes
II) Most CDRs are not immunogenic
III) Immunogenic CDRs can be de-immunized by site-specific engineering while maintaining complete biological function

Therefore, we propose a strategy based on antibody engineering to eliminate immunogenicity: reduce the immunogenicity potential by binding up to two amino acid substitutes in one epitope, while maintaining the natural binding characteristics.

This method has been successfully applied to the modification of mouse immunogenic antibody. Through a site-directed mutation of the immunogenic epitope gene of the variable region, it becomes a parent motif. In addition, the R3 region of the epidermal growth factor (EGF) receptor was blocked and 6 amino acids in the amphiphilic sequence were replaced by the expected residues of the homologous human sequence. This method has universal applicability and successfully reduces the immune response of non-human antibodies.

Features

Extensive experience: we have accumulated a wealth of project experience and expertise in the field of antibody engineering, and our experts can participate in each stage of your antibody drug development.
Reasonable design: through the transformation of antibody engineering technology, combined with existing knowledge, your antibody drugs can be ideally de-immunized.
Affordable: make the best service for your project at a competitive price.

Creative Biolabs owns professional antibody sequencing and antibody engineering technology platforms to remove immunogenicity. If you are interested in antibody engineering, please contact us and we will provide you with technical service and support as soon as possible.

Other optional RDIT^® antibody drug de-immunization services:

Reference

Santos, M. L., et al. Advances and challenges in therapeutic monoclonal antibodies drug development. Brazilian Journal of Pharmaceutical Sciences. 2018, 54. Distributed under Open Access license CC BY 4.0, without modification.

FAQ

What is antibody de-immunization?
Antibody de-immunization involves modifying therapeutic antibodies to reduce their immunogenicity, or the likelihood of triggering an immune response in patients. This process typically utilizes various engineering techniques to alter parts of the antibody that are recognized by the immune system, thus enhancing its compatibility and safety for clinical use.
How is antibody engineering used in de-immunization?
Antibody engineering for de-immunization involves techniques such as altering the amino acid sequence of the antibody to remove T-cell epitopes while maintaining its antigen-binding ability. Techniques like CDR grafting, humanization, and phage display are commonly employed to achieve these modifications effectively.
What are the benefits of antibody de-immunization?
The primary benefit of antibody de-immunization is the reduced risk of immune responses against the therapeutic antibody, which can lead to adverse effects and decreased efficacy. De-immunized antibodies can provide more consistent therapeutic results and improved patient tolerance, especially in chronic conditions requiring long-term treatment.
Can all antibodies be de-immunized?
While most antibodies can be engineered for reduced immunogenicity, the success of de-immunization depends on the specific characteristics of the antibody and its target. Factors such as the antibody's origin, structure, and the epitopes involved can influence the feasibility and outcome of the de-immunization process.
How is the effectiveness of de-immunized antibodies measured?
The effectiveness of de-immunized antibodies is typically assessed through preclinical and clinical trials that evaluate their safety, immunogenicity, and therapeutic efficacy. Analytical techniques such as ELISA, mass spectrometry, and immune assays are used to characterize the modified antibodies and their interaction with the immune system.